Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2554-2563

  Groll, Andreas H ^a   Wood, Lauren ^a   Roden, Maureen ^a   Mickiene, Diana ^a   Chiou, Christine C ^a   Townley, Ellen ^a   Dad, Luqman ^a   Piscitelli, Stephen C ^a   Walsh, Thomas J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN PLUS ITRACONAZOLE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; CYCLODEXTRIN; CYCLODEXTRIN ITRACONAZOLE; ITRACONAZOLE; PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANDIDA; CANDIDIASIS; CELL COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUTH INFECTION; OROPHARYNX; PHARMACODYNAMICS; PHARYNGITIS; PRIORITY JOURNAL; TREATMENT PLANNING; CANDIDA ALBICANS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECT; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHARYNX DISEASE; PRESCHOOL CHILD; THRUSH;

ADOLESCENT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDA ALBICANS; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLODEXTRINS; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMAN; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; PHARYNGEAL DISEASES; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS;

EID: 0035991864     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2554-2563.2002     Document Type: Article

References (36)

1. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers
2. Itraconazole solution: Higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis
3. Itraconazole cyclodextrin solution-effective treatment for HIV-related candidosis unresponsive to other azole therapy
4. Revised classification system for human immunodeficiency virus infection in children less then 13 years of age
5. Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography
6. Pharmacology of itraconazole
7. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children
8. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis
9. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders
10. Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules
11. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients
12. Drug therapy in pediatric patients
13. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
14. Antifungal pharmacodynamics: Concentration-effect relationships in vitro and in vivo
15. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum
16. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
17. Current approaches to diagnosis and treatment of fungal infections in children infected with human immunodeficiency virus
18. Preventing and treating azoleresistant oropharyngeal candidiasis in HIV-infected patients
19. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS
20. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: Correlation of clinical response with in vitro susceptibility
21. Drug interactions in patients infected with human immunodeficiency virus
22. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia
23. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients
24. Developmental ontogenic basis of drug disposition
25. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections
26. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients
27. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis
28. Itraconazole in cyclodextrin solution
29. Adverse events associated with itraconazole in 189 patients on chronic therapy
30. Antifungal drug resistance in pathogenic fungi
31. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole
32. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection
33. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
34. New targets and delivery systems for antifungal therapy